Results filed 3 November 2026 · Market cap ₹39,095 crore · PE 60.4
GrowthTranscript read
Revenue
+33.6%
on a year ago
EBITDA
+60.3%
on a year ago
Profit to shareholders
+38.3%
on a year ago
EBITDA margin
25.2%
+3.2 pts on last quarter
Medanta delivered a robust Q2 FY27 with revenue from operations growing 33.6% YoY to INR 14,690 million and operating EBITDA jumping 60.2% YoY to INR 3,701 million as margins reached 25.2%. Operational momentum was driven by high volume growth across network hospitals and Noida achieving EBITDA breakeven within its first year of operation. The company advanced its long-term expansion plan by acquiring land in Ghaziabad for a 500-bed hospital, supporting a broader 4-5 year pipeline to add ~3,450 beds across six greenfield projects.
Global Health Limited, Q2 FY27₹ crore, consolidated
Q2 FY27
Q1 FY27
vs previous quarter
Q2 FY26
vs a year ago
Revenue
1,469
1,304
+12.7%
1,099
+33.6%
Operating profit (EBIT)
299
218
+37.4%
181
+65.2%
Operating margin
20.4%
16.7%
+367 bps
16.5%
+389 bps
Other income
23.61
22.16
+6.5%
19.73
+19.7%
Exceptional items
0
0
–
15.98
–
Profit before exceptional items and tax
295
213
+38.2%
184
+60.4%
Profit to shareholders
219
159
+38.1%
158
+38.3%
Earnings per share (₹)
8.21
5.91
+38.9%
5.89
+39.4%
Source: Global Health Limited’s filing to NSE, 3 November 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
What stood out
Noida hospital turned EBITDA positive within one year of inaugurationSourceMedanta Noida posted revenue of INR 1,059 million and operating EBITDA of INR 86 million in Q2 FY27 versus an EBITDA loss of INR 199 million in Q2 FY26 (Press Release, orig page 2; Presentation, page 9).
Consolidated operating EBITDA grew 60.2% YoY with margins expanding 418 bps to 25.2%SourceOperating EBITDA rose from INR 2,310 million (21.0% margin) in Q2 FY26 to INR 3,701 million (25.2% margin) in Q2 FY27 (Press Release, orig page 2).
Cluster 2 hospitals operating EBITDA surged 110.0% YoY to INR 1,837 millionSourceCluster 2 revenue grew 63.2% YoY to INR 5,790 million while operating EBITDA grew 110.0% YoY with margins expanding to 31.7% from 24.7% (Presentation, page 16).
Approval and land acquisition for a new 500-bed hospital project in GhaziabadSourceAllotted 2.61-acre land parcel via e-auction for INR 1,658.2 million (INR 166 crore) with Board approving a 500-bed hospital project with total capex of ~INR 1,000 crore (Transcript, orig page 5; Press Release, orig page 5).
Addition of ~3,450 beds across 6 greenfield hospitals to reach over 7,600 beds, backed by planned capital expenditure of ~INR 62,390 million (>INR 6,000 crore)
Next 4 to 5 years (FY28 to FY31)
Tailwinds
Strong patient footfalls and volume-driven revenue growth across facilitiesSourceIn-patient volumes grew 29.5% YoY to 65,956 and out-patient encounters increased 37.9% YoY to 1,228,614 (Presentation, page 31).
Significant operating leverage from newly scaled beds and mature unitsSourceOccupied bed days grew 22.4% YoY to 190,600 with network occupancy increasing from 63.7% to 66.5% on higher census beds (Presentation, page 31).
Robust international patient revenue growthSourceInternational patient revenue increased 30.3% YoY to INR 993 million during Q2 FY27 (Press Release, orig page 3).
Reduction in Average Length of Stay (ALOS)SourceNetwork ALOS dropped from 3.06 days in Q2 FY26 to 2.89 days in Q2 FY27, improving bed turnover (Presentation, page 6).
Headwinds
Execution delay in Pitampura hospital projectSourcePankaj Sahni noted Pitampura is progressing slower than planned due to revisions in drawings and approvals under the NBC 2026 standard (Transcript, orig page 10; Presentation, page 19).
Seasonal construction slowdown risks in Delhi NCRSourceSouth Delhi project at GK may face temporary slowdowns or stoppages over the next 1-2 months due to winter pollution norms (Pankaj Sahni, Transcript, orig page 9).
Near-term Q3 seasonality softnessSourceCFO Yogesh Gupta indicated Q3 is normally softer due to the festival season alongside continued doctor hiring costs (Transcript, orig page 9).
New businesses and products
new geography · Land acquired via e-auction; Board approved project; applying for approvals
Ghaziabad Greenfield Hospital
Expected benefit
Expand presence in Delhi NCR and cater to Eastern UP catchment areas (Meerut, Hapur, Bulandshahr)
Risks
Regulatory approvals and construction timeline execution
Timeline
Next 4 to 5 years
Investment
INR 1,658.2 million land cost; estimated capex of approx INR 9,820 million to INR 9,970 million (~INR 1,000 crore)
High long-term capital expenditure commitment relative to current cash balancesSourcePlanned capex of INR 62,390 million over the next 4-5 years will require sustained high cash generation or substantial debt addition relative to current net cash of INR 7,815 million (Presentation, page 18, 21).
How the call went
The call offered solid transparency regarding operational performance, corporate expense allocation, and pipeline timelines, though management resisted providing hospital-level realizations and consumable margin details.
Specific or vague
Management provided detailed metrics for cluster performance, beds, and project execution schedules, but explicitly declined to disclose individual hospital-level ARPPs and consumable cost breakdowns.
Candour
Management was open regarding project delays (Pitampura), winter pollution stoppages, and clarified that corporate overheads are entirely loaded onto Gurugram/Cluster 1.
The hard questions
Directly addressed queries on Cluster 2 margin sustainability, government oncology pricing caps, and the risks of large-format initial capacity investments.
What analysts pressed on
Sustainability of Cluster 2 EBITDA margins (31.7%) and corporate cost allocations
Potential impact on profitability from proposed government caps on oncology drug margins
Slow growth in ARPP and lack of tariff increases across developing facilities
Timelines and approval progress across greenfield pipeline projects
Answers that sidestepped
Refused to give unit-level ARPPs or ARPOBs for Lucknow, Patna, and Noida, restricting disclosure strictly to cluster levels (Yogesh Gupta, Transcript orig page 8).
Declined to disclose the revenue and EBITDA contribution from drugs and consumables, stating they do not track numbers that way (Yogesh Gupta, Transcript orig page 13-14).
Numbers against the story
The reported figures strongly align with management's narrative of volume-led growth rather than price realization. Consolidated revenue grew 33.6% YoY and operating EBITDA grew 60.2% YoY, supported by a 29.5% increase in inpatient volumes while ARPP grew by only 2.7%. The massive margin improvement in Cluster 2 (from 24.7% to 31.7%) corroborated management's statement regarding the turnaround of Noida from an operating loss of INR 199 million to positive INR 86 million alongside operating leverage in Lucknow and Patna.
Figures: the company’s results filing with NSE, linked under the table.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.